Cholestyramine and Zemplar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cholestyramine (cholestyramine) and Zemplar (paricalcitol). Common drug interactions include nephrogenic systemic fibrosis among females and oedema peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Cholestyramine and Zemplar. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Cholestyramine?

Cholestyramine has active ingredients of cholestyramine. It is often used in diarrhea. eHealthMe is studying from 9,893 Cholestyramine users. Check the latest studies of Cholestyramine.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.



On Jul, 26, 2026

22 people who take Cholestyramine and Zemplar together, and have interactions are studied.

Cholestyramine and Zemplar drug interactions.

What are the common drug interactions of Cholestyramine and Zemplar, by gender? *:

female:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Burning sensation
  3. Chest pain
  4. Drug hypersensitivity
  5. Dyskinesia (abnormality or impairment of voluntary movement)
  6. Dyspnoea (difficult or laboured respiration)
  7. Electrocardiogram t wave inversion
  8. Erythema (redness of the skin)
  9. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  10. Hypokalaemia (low potassium)

male:

  1. Oedema peripheral (superficial swelling)
  2. Abscess jaw (tooth abscess or root abscess)
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Bacteraemia (presence of bacteria in the blood)
  5. Benign prostatic hyperplasia (benign enlargement of the prostate)
  6. Bicytopenia (two parameters from the full blood count are low, the term bicytopenia can be used)
  7. Bundle branch block right (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the right ventricle)
  8. Calcium metabolism disorder (occur when the body has too little or too much calcium)
  9. Cardiac failure congestive
  10. Cardiomegaly (increased size of heart than normal)

What are the common drug interactions of Cholestyramine and Zemplar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Renal transplant

30-39:

n/a

40-49:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)

50-59:

  1. Chronic kidney disease
  2. Drug hypersensitivity
  3. Dyskinesia (abnormality or impairment of voluntary movement)
  4. Dyspnoea (difficult or laboured respiration)
  5. Electrocardiogram t wave inversion
  6. Erythema (redness of the skin)
  7. Hypokalaemia (low potassium)
  8. Hypotension (abnormally low blood pressure)
  9. Lip swelling
  10. Slow response to stimuli (slow response by nerves)

60+:

  1. Nephrogenic anaemia (anaemia due to kidney disease)
  2. Abscess jaw (tooth abscess or root abscess)
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Bacteraemia (presence of bacteria in the blood)
  5. Benign prostatic hyperplasia (benign enlargement of the prostate)
  6. Bicytopenia (two parameters from the full blood count are low, the term bicytopenia can be used)
  7. Bundle branch block right (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the right ventricle)
  8. Calcium metabolism disorder (occur when the body has too little or too much calcium)
  9. Cardiac failure congestive
  10. Cardiomegaly (increased size of heart than normal)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 8 people, 36.36%
  2. Pain: 5 people, 22.73%
  3. High Blood Pressure: 4 people, 18.18%
  4. High Blood Cholesterol: 4 people, 18.18%
  5. Swelling: 3 people, 13.64%
  6. Infection: 3 people, 13.64%
  7. Fluid Retention (an abnormal accumulation of fluid in the blood): 3 people, 13.64%
  8. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 13.64%
  9. Headache (pain in head): 2 people, 9.09%
  10. Chronic Renal Failure (kidney failure): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cholestyramine and Zemplar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cholestyramine and Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cholestyramine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cholestyramine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zemplar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cholestyramine and paricalcitol (the active ingredients of Cholestyramine and Zemplar, respectively), and Cholestyramine and Zemplar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: